Fillable Printable Approved Meeting Minutes
Fillable Printable Approved Meeting Minutes
Approved Meeting Minutes
Douglas A. Ducey, Governor
Thomas J. Betlach, Director
801 East Jefferson, Phoenix, AZ 85034 • PO Box 25520, Phoenix, AZ 85002 •
602-417-4000 •
www.azahcccs.gov
AHCCCS
Pharmacy and Therapeutics Committee Meeting Minutes
May 17, 2016
12:00PM- 4:00 PM
701 E. Jefferson Phoenix, AZ 85034- Gold Room- 3
rd
Floor
Members Present:
Dan Lindell
Stephen Chakmakian
James Hargrave
Lydia Nesemann
Robert Marotz
Berkley Olvera
Cindy Komar
Gloria Abril
Shawn McMahon
Otto Uhrik
Kathleen Bryant
Suzanne Campbell
Mohamad Ramadan
AHCCCS Staff:
Sara Salek
Suzi Berman
Robin Davis
Lauren Prole
Kathy Bashor
Magellan Medicaid Admin:
Doug Brown
Rick Pope
Members via teleconference:
None
Members Absent:
Olivia Young
Joanna Kowalik
AHCCCS P&T Meeting Minutes
Page 2 of 9
WELCOME AND INTRODUCTIONS: SARA SALEK, M.D., CHIEF MEDICAL OFFICER, AHCCCS
1. Dr. Sara Salek called the meeting to order at 12:00 PM and welcomed committee members, staff, and
guest speakers.
AHCCCS and Behavioral Health Drug Lists
SUPPLEMENTAL REBATE CLASS REVIEW
1. Substance Use Disorder
a. Clinical review: Provider Synergies – Doug Pope
b. Pharma Testimony:
i. Deborah Profant: Alkermes: Vivitrol
ii. William Mullen: Indivior: Suboxone
iii. Thomas Begres: Adapt Pharma: Narcan Nasal Spray
iv. J Carvel Jackson: Orexo: Zubsolv
c. Public Testimony:
i. Michael Sucher
ii. Lloyd Vacovsky
iii. Doray Elkins
iv. Kathleen Adams
2. Hepatitis C
a. Clinical review: Provider Synergies Rick Pope
b. Pharma Testimony:
i. Coleen Fong: Gilead: Harvoni
ii. Laura Hill: Abbvie: Viekira Pak
iii. John Michael Thomas: Bristol Myers Squibb: Daklinza
iv. Ralph Gualtieri: Merck: Zepatier
c. Public Testimony:
AHCCCS P&T Meeting Minutes
Page 3 of 9
i. Mark Wong
3. Hypoglycemics: Incretin Mimetics/Enhancers
a. Clinical review: Provider Synergies Dr. Pope
b. Pharma Testimony:
i. Michele Jones: Novo Nordisk: Victoza
ii. Ralph Gualtieri: Merck: Januvia
iii. William O’Neill: Boehringer Ingelheim: Jardiance, Glyxambi, Tradjenta
c. Public Testimony – None
4. Hypoglycemics: Insulin and Related Agents
a. Clinical review: Provider Synergies Rick Pope
b. Pharma Testimony
i. Michele Jones: Novo Nordisk: Tresiba, Levemir, Novolog
ii. Nana Numapau: Sanofi: Toujeo
c. Public Testimony – None
5. COPD
a. Clinical review: Provider Synergies Rick PopPharma Testimony
i. William O’Neill (Boehringer Ingelheim) Spiriva, Stiolto
b. Public Testimony – None
6. Executive Session-Closed to the public
7. Class Votes
a. Opioid Dependence Treatment
i. Committee members voted unanimously to add the following to the AHCCCS Drug List as
preferred products. No members opposed or abstained.
1. Naloxone vial and syringe
2. Naloxone Nasal spray (Narcan)
3. Naltrexone oral (ReVia)
4. Naltrexone ER injectable suspension (Vivitrol)
a. Remove PA
5. Buprenorphine/naloxone sublingual flim (Suboxone)
a. Remove PA
b. No Grandfathering
AHCCCS P&T Meeting Minutes
Page 4 of 9
ii. Committee members voted unanimously to add the following to the AHCCCS Drug List as
preferred products. No members opposed or abstained.
1. Naloxone vial and syringe (soluation for injection)
2. Naloxone Nasal Spray (Narcan)
b. Hepatitis C Agents
i. Committee members voted unanimously to add the following to the AHCCCS Drug List as
preferred products. No members opposed or abstained.
1. Peg-Intron
2. Pegasys Vial, ProClick, Syringe
3. Ribavirin tablet and capsule
4. Zepatier
5. Technivie
6. Viekira
7. Daklinza
8. Harvoni (currently preferred)
9. Sovaldi (currently preferred)
c. Hypoglycemics, Incretin Mimetics/Enhancers
i. Committee members voted unanimously to add the following to the AHCCCS Drug List as
preferred products with grandfathering in place for all except Bydureon pen. No members
opposed or abstained.
1. Janumet
2. Janumet XR
3. Januvia
4. Jentadueto
5. Tradjenta
6. Byetta Pens
7. Symlin Pens
8. Victoza
d. Hypoglycemics, Insulin and Related Agents
i. Committee members voted unanimously to add the following to the AHCCCS Drug List as
preferred products with no grandfathering. PA status on pen products will be determined
after further review. No members opposed or abstained.
1. Humalog vial and pen
2. Humalog mix vial and pen
3. Humulin 70/30 vial
4. Humulin vial
AHCCCS P&T Meeting Minutes
Page 5 of 9
5. Humulin 500 U/M vial and pen
6. Levemir vial and pen
7. Lantus Solostar Pen
8. Lantus vial
e. COPD Agents
i. Committee members voted unanimously to add the following to the AHCCCS Drug List as
preferred products with no grandfathering. No members opposed or abstained.
1. Ipratropium inhalation solution
2. Ipratropium/albuterol inhalation solution
3. Spiriva
4. Atrovent HFA
5. Combivent Respimat
APPROVAL OF FEBRUARY 2016 P&T MEETING MINUTES
1. Motion made by Lydia Nesemann to approve February 2016 meeting minutes
2. Motion seconded by Dr. Marotz
3. 10 committee members voted in favor of approving the minutes
4. 0 committee members opposed
5. 1 committee member abstained
HCV PRIOR AUTHORIZATION CRITERIA: SUZI BERMAN
The HCV PA Criteria is currently being revised and will be sent out for public comment.
NEW DRUG REVIEWS: NON-SUPPLEMENTAL REBATE CLASS: RICK POPE/SUZI BERMAN
1. Oncology:
a. Recommendation made to form subcommittee to review oral oncology agents
i. 8 committee members voted in favor
ii. 0 committee members opposed
iii. 3 committee members abstained
AHCCCS P&T Meeting Minutes
Page 6 of 9
b. Alecensa
i. Recommendation is to add Alecensa to the AHCCCS drug list with PA
1. Motion made by Dr. Chakmakian to add Alecensa with PA
2. Motion seconded by Dr. Marotz
3. All committee members voted in favor of the motion
4. No committee members opposed or abstained
c. Cotellic
i. Recommendation to add Cotellic to the AHCCCS drug list with PA
1. Motion made by Dr. Chakmakian to add Cotellic with PA
2. Motion seconded by Lydia Nesemann
3. All committee members voted in favor of the motion
4. No committee members opposed or abstained
d. Ninlaro
i. Recommended to add Ninlaro to the AHCCCS drug list with PA
1. Motion made by Dr. Chakmakian to add Ninlaro with PA
2. Motion seconded by Dr. Marotz
3. All committee members voted in favor of the motion
4. No committee members opposed or abstained
e. Tagrisso
i. Recommended to add Tagrisso to the AHCCCS drug list with PA
1. Motion made by Dr. Chakmakian to table in order to research further
2. Motion seconded by Kathleen Bryant
3. All committee members voted in favor of the motion
4. No committee members opposed or abstained
2. Aristada (LAI)
a. Recommendation is to not add Aristada to the AHCCCS Drug List or the Behavioral Health Drug List
and review the long-acting injectable atypical antipsychotics as a supplemental rebate therapeutic
class after July 1st.
i. Motion made by Kathleen Bryant to table until after July 1
st
ii. Motion seconded by Dr. Chakmakian
iii. All committee members voted in favor of the motion
iv. No committee members opposed or abstained
3. Belbuca (narcotic, long acting)
a. Recommendation is to not add Belbuca to the AHCCCS Drug List because there are many other long-
acting agents available that are more cost-effective.
AHCCCS P&T Meeting Minutes
Page 7 of 9
i. Motion made by Dan Lindell to table and review entire class of Opioids for supplemental
rebate
ii. Motion seconded by Dr. Ramadan
iii. All committee members voted in favor of the motion
iv. No committee members opposed or abstained
4. Dyanavel XR (stimulants)
a. Recommendation is to not add Dyanavel XR to the AHCCCS Drug List or the Behavioral Health Drug
List because there are other more cost effective stimulants available on these drug lists.
i. Motion Made by Dr. Chakmakian to remain off of the AHCCCS Drug List
ii. Motion seconded by Lydia Nesemann
iii. All committee members voted in favor of the motion
iv. No committee members opposed or abstained
5. Genvoya (HIV/AIDS)
a. Recommendation is to add Genvoya to the AHCCCS Drug List with prior authorization.
i. Motion made by Dan Lindell to add to the AHCCCS Drug list with no prior authorization
ii. Motion seconded by Dr. Marotz
iii. 5 committee members voted in favor of the motion
iv. 0 committee members Opposed
v. 6 committee members Abstained
6. Invega Trinza (LAI)
a. Recommendation is not to add Invega Trinza to the AHCCCS drug list and review as a supplemental
rebate therapeutic class after July 1st.
i. Motion made by Kathleen Bryant to table and review entire class after July 1
st
.
ii. Motion seconded by Lydia Nesemann
iii. All committee members voted in favor of the motion
iv. No committee members opposed or abstained
7. Keveyis (CAI)
a. Recommendation to add Keveysis wot the AHCCCS drug list with prior authorization
i. Motion made by Lydia Nesemann to leave off of the AHCCCS drug list as a non preferred
agent and make available via PA only.
ii. Motion seconded by Dr. Chakmakian
iii. 10 committee members voted in favor of the motion
iv. No committee members opposed
v. 1 committee member abstained
AHCCCS P&T Meeting Minutes
Page 8 of 9
8. Quillichew ER (stimulants)
a. Recommended to not add Quillichew ER to the AHCCCS or Behavioral Health drug list because many
other Methylphenidate products are more cost effective.
i. Motion made by Dr. Chakmakian to leave off of the AHCCCS and Behavioral Health Drug lists.
ii. Motion seconded by Kathleen Bryant
iii. All committee members voted in favor of the motion
iv. No committee members opposed or abstained
9. Uptravi (PAH)
a. Recommended to not add Uptravi to the AHCCCS drug list as there are several other options
currently available on the drug list.
i. Motion made by Lydia Nesemann not to add Uptravi to the AHCCCS drug list
ii. Motion seconded by Kathleen Bryant
iii. All committee members voted in favor of the motion
iv. No committee members abstained
10. Rexulti (antipsychotic/MDD)
a. Recommendation is not to add Rexulti to the AHCCCS preferred drug list or the Behavioral Health
drug list
i. Motion made by Kathleen Bryant to table until after July 1
st
ii. Motion seconded by Dan Lindell
iii. All committee members voted in favor of the motion
iv. No committee members opposed or abstained
BIOLOGIC UPDATE: SUZI BERMAN
1. Glatopa (Biosimilar for Copaxone)
a. Per the AHCCCS Medical Policy Manual: Policy 310V:
i. AHCCCS Contractors shall not transition to a biosimilar drug until AHCCCS has determined
that the biosimilar drug is overall more cost-effective to the state than the continued use of
the brand name drug.
b. AHCCCS and its contractors shall continue to cover only the brand name Copaxone because it is
more cost effective than Glatopa.
AHCCCS P&T Meeting Minutes
Page 9 of 9
P&T OPERATIONAL POLICY: SARA SALEK
Discussion Tabled until August 2017 P&T meeting
AGENDA ITEMS FOR AUGUST 16, 2016 P&T: ALL
Please email Suzi Berman any requests for agenda items for the August 2016 meeting.
ADJOURNMENT
The meeting adjourned at 5:20 PM
Minutes recorded by Robin Davis
____________________________________________ _____________
Suzi Berman, RPh Date
Director of Pharmacy Services
AHCCCS
